🔎 Trials Near Me

Home › Post-Traumatic Stress Disorder › NCT02560805

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

RecruitingPhase 2Healthy volunteers welcome

Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II

Who can join

Ages 18 to 65 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* veterans ages 18-65 years old with PTSD and without PTSD (controls) matched for age, gender, and race.

Exclusion Criteria:

* pregnancy
* hypertension
* diabetes
* heart or vascular disease
* illicit drug use
* excessive alcohol use (\>2 drinks per day)
* hyperlipidemia
* autonomic dysfunction
* current treatment with clonidine, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARBs)
* treatment with monoamine oxidase (MAO) inhibitors within the last 14 days
* any serious systemic disease
* chronic kidney disease defined as estimated glomerular filtration rate (GFR) \< 60 cc/min
* hyperkalemia (serum potassium \> 5 meq/dL)
* systolic blood pressure \< 100 mm Hg
* diastolic blood pressure \< 60 mm Hg
* heart rate \< 50 beats/min
* known hypersensitivity to ARBs or beta blockers

About the study

The purpose of this study is to find out why patients with post-traumatic stress disorder (PTSD) have an increased risk for heart disease and high blood pressure later in life. A second purpose is to find out what causes PTSD patients to have high adrenaline levels during stress. This study will also test if a medicine called losartan improves high adrenaline levels in patients with PTSD and if a certain gene that has to do with high blood pressure might be associated with high adrenaline levels.

What is being tested

Sponsor: Emory University · Participants: 134 · Started: 2015-10

Contact the study team

Official record on ClinicalTrials.gov — NCT02560805

Locations in the U.S.

GeorgiaAtlanta VA Medical Center, Decatur

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.